- Israel-based RedHill Biopharma ( NASDAQ: RDHL ) on Tuesday said results from its phase two study of its antiviral RHB-107 for the treatment of COVID-19 was published in the peer-reviewed International Journal of Infectious Diseases.
- U.S.-listed shares of the micro-cap specialty biopharma rose 21.2% to $0.17 in premarket trading.
- The mid-stage study showed that RHB-107 successfully met the main goal of safety and tolerability and delivered promising efficacy results including faster recovery from severe COVID symptoms and 100% reduction in hospitalization due to COVID, RDHL said in a statement .
- The study had enrolled a total of 61 patients.
- RDHL said it was in "advanced discussions" regarding inclusion of once-daily oral RHB-107 in a multinational platform trial for COVID outpatients.
- The company added that it was also in discussions for external funding for its late-stage COVID development.
For further details see:
RedHill shares gain 21% on peer-reviewed data publication of its COVID-19 antiviral